Premium
SPINAL BONE MINERAL CONTENT IN MYXOEDEMA AND THYROTOXICOSIS. EFFECTS OF THYROID HORMONE(S) AND ANTITHYROID TREATMENT
Author(s) -
KRØLNER B.,
JØRGENSEN J. VESTERDAL,
NIELSEN S. PORS
Publication year - 1983
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1983.tb02873.x
Subject(s) - euthyroid , medicine , osteopenia , levothyroxine , endocrinology , bone mineral , thyroid , bone remodeling , hormone , antithyroid agent , osteoporosis , graves' disease
SUMMARY The effects of thyroid hormones and antithyroid treatment upon lumbar spine bone mineral content (lumbar BMC) were studied in a consecutive series of patients with myxoedema and thyrotoxicosis, respectively. All patients were investigated in the untreated state and 3‐monthly during appropriate treatment for 1 year by using dual‐photon [ 153 Gd] absorptiometry. Patients with myxoedema ( n = 8) did not differ from normal individuals as regards initial lumbar BMC, but levothyroxine‐treatment caused significant reduction in this variable. The median decrease in lumbar BMC after 1 year was 8·9% (95% confidence limits 1·5–15·4%, P < 0·05). This loss of bone might be attributed to an inappropriate increase in bone turnover in the euthyroid state. It is as yet uncertain whether it predisposes to spinal osteopenia. Median lumbar BMC in patients with thyrotoxicosis ( n = 25) was 12·6% (2·0–16·6%, P < 0·05) lower than that of normal individuals before the beginning of treatment. Lumbar BMC increased during antithyroid therapy. The median gain in bone mineral after 1 year was 3·7% (1·6–9·6%, P < 0·01). These findings suggest that excess of thyroid hormones leads to negative spinal bone mineral balance. The revealed bone loss was clinically insignificant, however, and it appeared to be at least partially reversible after antithyroid treatment.